SASarah Arrowsmith

Sarah Arrowsmith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Arrowsmith has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Susan Wray

    Department of Molecular and Cellular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

    11 shared publications
  • Susan Wray

    Harris-Wellbeing Research Centre, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK

    7 shared publications
  • Christian Werner Gruber

    Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna

    5 shared publications
  • Markus Muttenthaler

    Faculty of Chemistry Institute of Biological Chemistry University of Vienna Vienna Austria

    4 shared publications
  • James Neilson

    Department of Women's and Children's Health, the Institute of Translational Medicine, University of Liverpool, Liverpool, UK

    3 shared publications
  • Karen Noble

    Department of Cellular and Molecular Physiology; Institute of Translational Medicine; University of Liverpool; Liverpool Women's Hospital; Liverpool UK

    3 shared publications

Latest Publications

  • Open Access

    Maternal Adipokines During Labour In Women With Obesity: Associations Of Leptin And Visfatin With Labour Duration And Obstetric Outcomes

    by Oskar Nydal, Sarah Arrowsmith, Maria Svenvik, Sofia Nevander, Marie Blomberg, Sara Carlhäll

    Background: Prolonged labour and operative delivery are more common among women with obesity, suggesting impaired myometrial contractility, although the underlying mechanisms remain unclear. Adipokines have been proposed as potential mediators in these processes due to their contractility inhibiting properties in vitro. The objective was to examine associations between maternal plasma leptin and visfatin concentrations during labour and labour outcomes related to impaired uterine contractility in women with obesity.Methods: In this prospective cohort study, 262 women with obesity (BMI ≥ 30) provided plasma samples during active labour. Participants were categorized into groups based on percentiles of maternal leptin and visfatin concentrations within the cohort (<25th, 25–<75th and ≥75th percentiles for each adipokine). Maternal and obstetric outcomes were compared across groups. Correlations with BMI were assessed, and associations with labour duration were evaluated using linear regression and Kaplan-Meier analyses.Findings: Leptin concentrations correlated positively with BMI (r = 0·300, p < 0·001), whereas visfatin did not (r = 0·094, p = 0·14). Prolonged active labour was more common among women with high leptin concentrations (p = 0·02). Higher leptin concentrations were independently associated with longer labour duration (+1·44 min/ng/mL, p = 0·03). Visfatin was not independently associated with longer labour duration. There was a possible lower probability for birth at a specific timepoint for women with concomitantly high leptin and visfatin levels, consistent with a potential additive effect (p 0·89 for difference across all groups).InterpretationAmong women with obesity, elevated maternal leptin during labour was associated with increasing BMI and longer labour duration, supporting a potential role in obesity-related labour dysfunction, whereas visfatin showed no independent associations.Funding: This research was supported by the Swedish Research Council for Health, Working Life and Welfare (FORTE) through the Centre Grant for Women’s Health (MAMA Research HUB) (MB), and research grants from Region Östergötland (SC), Medical Research Council of Southeast Sweden (SC), research grant from Region Kalmar County (ON). The funders had no part in the process of study design, writing, or publication.

  • The effect of the use of e-cigarettes during pregnancy on maternal, fetal and infant health outcomes: A scoping review protocol

    by Stella Fielder, Chloe Barnes, Laura Ormesher, Rehan Junejo, Sarah Arrowsmith, Alexander Heazell

    INPLASY202490123 The effect of the use of e-cigarettes during pregnancy on maternal, fetal and infant health outcomes: A scoping review protocol Keywords: Vaping; e-cigarette; electronic cigarette;…


  • Open Access

    A hydrogen sulphide-releasing non-steroidal anti-inflammatory, ATB-346, significantly attenuates human myometrial contractions

    by Ana Mijušković, Susan Wray, Sarah Arrowsmith

    Background: Spontaneous preterm birth is the leading cause of perinatal morbidity and mortality. Tocolytics are drugs used to inhibit uterine contractions in cases of imminent preterm birth, however, few are effective in stopping labour once initiated and all have side effects. Combination approaches involving drugs that target multiple signalling pathways that regulate contractions may increase efficacy, reduce dosage and improve tolerability. Both non-steroidal anti-inflammatory drugs (NSAIDs) and hydrogen sulphide (H2S)-releasing compounds can reduce myometrial contractions. In a novel approach we evaluated the tocolytic properties of ATB-346–a H2S-releasing derivative of the NSAID naproxen, shown clinically to reduce pain and inflammation in arthritis. Methods: Using organ baths, paired strips of human myometrium were exposed to increasing concentrations of ATB-346, or equimolar concentrations (10µM and 30µM) of the parent drug, naproxen, or the H2S-releasing moiety, 4-hydroxy-thiobenzamide (TBZ), alone. The ability of ATB-346 versus the individual components of ATB-346 to decrease ex vivo spontaneous contractions was investigated, and the potency was compared to a known H2S donor, Na2S. Results: Acute application of Na2S produced a concentration-dependent decrease in force amplitude and force integral (area under the curve) of contraction. ATB-346 produced a more profound decrease in contraction compared to equimolar concentrations of naproxen or TZB alone and was more potent than the equivalent concentration of Na2S. Conclusions: ATB-346 exhibits potent tocolytic properties in human myometrium. These exciting results call for further exploration of ATB-346, with a view to repurposing this or similar drugs as novel therapies for delaying preterm labour.


  • Open Access

    Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions

    by Jessica Taylor, Andrew Sharp, Steve P. Rannard, Sarah Arrowsmith, Tom O. McDonald

    The World Health Organisation (WHO) estimates 15 million babies worldwide are born preterm each year, with 1 million infant mortalities and long-term morbidity in survivors. Whilst the past 40 years have provided some understanding in the causes of preterm birth, along with development of a range of therapeutic options, notably prophylactic use of progesterone or uterine contraction suppressants (tocolytics), the number of preterm births continues to rise. Existing therapeutics used to control uterine contractions are restricted in their clinical use due to pharmacological drawbacks such as poor potency, transfer of drugs to the fetus across the placenta and maternal side effects from activity in other maternal systems. This review focuses on addressing the urgent need for the development of alternative therapeutic systems with improved efficacy and safety for the treatment of preterm birth. We discuss the application of nanomedicine as a viable opportunity to engineer pre-existing tocolytic agents and progestogens into nanoformulations, to improve their efficacy and address current drawbacks to their use. We review different nanomedicines including liposomes, lipid-based carriers, polymers and nanosuspensions highlighting where possible, where these technologies have already been exploited e.g. liposomes, and their significance in improving the properties of pre-existing therapeutic agents within the field of obstetrics. We also highlight where active pharmaceutical agents (APIs) with tocolytic properties have been used for other clinical indications and how these could inform the design of future therapeutics or be repurposed to diversify their application such as for use in preterm birth. Finally we outline and discuss the future challenges.


  • Human Myometrial Contractility Assays

    by Sarah Arrowsmith

    Traditional contractility assays using an organ bath setup consist of several chambers (or baths) perfused with temperature-controlled, oxygenated physiological saline. Strips or rings of tissue (usually smooth or cardiac muscle) are mounted within the organ bath between a fixed hook and an isometric force transducer. The contraction force is recorded by the transducer and different parameters of contraction are analyzed. Different experimental protocols can be performed to investigate the effect of drugs and reagents on tissue contractility to investigate tissue physiology or determine the in vivo potential of novel pharmaceutical compounds. Here, the application of a modified organ bath to measure ex vivo contractions of small strips of human uterine smooth muscle (myometrium) is described, as well as protocols to study the effect of oxytocin and uterine relaxants on contraction.


  • Open Access

    Identification and validation of suitable reference genes for quantitative real-time PCR gene expression analysis in pregnant human myometrium

    by Sarah Arrowsmith

    Accurate quantification of quantitative PCR (qPCR) data requires a set of stable reference genes (RGs) for normalisation. Despite its importance to mechanistic studies, no evaluation of RG stability has been conducted for pregnant human myometrium. A systematic search of the literature was performed to identify the most used RGs in human myometrial gene expression studies. The stability of these genes, and others, was then evaluated using geNorm and NormFinder algorithms, in samples of myometrium from singleton or twin pregnancies (n = 7 per group) delivering at term or preterm. The most frequently cited RGs wereGAPDH, ACTB, B2M and 18s.There was strong agreement between algorithms on the most and least stable genes: Both indicatedCYC1, YWHAZandATP5Bwere the most stably expressed. Despite being some of the most used RGs,B2M,18sandACTBexpression was least stable and was too variable for use as accurate normalisation factors. Pairwise variation analysis determined that the optimal number of RGs for accurate normalisation is two. Validation of the choice of RGs by comparing relative expression of oxytocin receptors (OXTR)using the least stable18sandB2M, with the most stable,CYC1andYWHAZ, erroneously demonstrated significantly increasedOXTRexpression in myometrium in singleton pregnancies compared to twins. This study demonstrates the importance of appropriate RG selection for accurate quantification of relative expression in pregnant human myometrium qPCR studies. For normalisation, the geometric mean ofCYC1andYWHAZ or ATP5Bis suggested. The use ofACTB, 18sandB2M, is not recommended.


  • Open Access

    Comparison of the myometrial transcriptome from singleton and twin pregnancies by RNA-Seq

    by Sarah Arrowsmith, Yongxiang Fang, Andrew Sharp

    Preterm birth is recognized as the primary cause of infant mortality worldwide. Twin pregnancies are significantly more at risk of preterm birth than singleton pregnancies. A greater understanding of why this is and better modes of treatment and prevention are needed. Key to this is determining the differing pathophysiological mechanisms of preterm birth in twins, including the role of the myometrium and premature uterine contraction. We performed RNA sequencing (RNA-Seq) of human myometrium from singleton and twin pregnancies at term (> 37+0 weeks) and preterm (< 37+0 weeks), collected during pre-labour Caesarean Section. RNA-Seq libraries were prepared from polyA-selected RNA and sequenced on the Illumina HiSeq 4000 platform. Differentially expressed genes (DEGs), GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment were conducted using R software. Significance was determined with a false discovery rate–adjusted P value of <0.05. Only 3 DEGs were identified between gestational age-matched singleton and twin myometrium and only 1 DEG identified between singleton term and twin preterm tissues. Comparison of singleton preterm myometrium with twin term myometrium however, revealed 75 down-regulated and 24 up-regulated genes in twin myometrium. This included genes associated with inflammation and immune response, T cell maturation and differentiation and steroid biosynthesis. GO and KEGG enrichment analyses for biologically relevant processes and functions also revealed several terms related to inflammation and immune response, as well as cytokine-cytokine receptor interaction and chemokine receptor signalling. Data indicate that little or no differences exist in the transcriptome of singleton and twin myometrium when matched for gestational age. The significant up- and down-regulation of genes identified between preterm singleton and twin myometrium at term may point to transcriptome changes associated with the chronic levels of uterine stretch in twin pregnancy or genes associated with the myometrium transitioning to labour onset.


  • Gestational and Hormonal Effects on Magnesium Sulfate’s Ability to Inhibit Mouse Uterine Contractility

    by Blessing E. Osaghae, Sarah Arrowsmith, Susan Wray

    Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.